BAYRY Stock Recent News
BAYRY LATEST HEADLINES
German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.
Bayer A.G. (OTCPK:BAYZF) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Jost Reinhard - Senior VP & Head of Investor Relations Rodrigo Santos - Member of Management Board & President of the Crop Science Division Stefan Oelrich - Head of the Pharmaceuticals Division & Member of the Board of Management William N. Anderson - Chairman of the Management Board & CEO Wolfgang U.
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.
Bayer Aktiengesellschaft raised its 2025 sales and earnings guidance, reflecting improved performance in its pharmaceuticals division and better-than-expected results. Litigation risks have eased significantly, with major Roundup settlements reducing future legal expenses and enhancing financial visibility. Despite a still-challenged balance sheet and negative net income margin, profitability is expected to improve as litigation costs decline.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
CNBC's Joe Kernen reports on the latest news.
German pharmaceutical company Bayer said on Thursday it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions to address ongoing Roundup litigation in the United States.
A French court ruled on Thursday that a complaint brought by a family against Bayer claiming their son's disabilities were the result of his mother's exposure to glyphosate when pregnant was inadmissible, local media reported.